

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 May 2023 (19.05.2023)



(10) International Publication Number
WO 2023/086363 A3

(51) International Patent Classification:

A61K 9/00 (2006.01) A61N 5/00 (2006.01)
A61K 31/472 (2006.01) A61P 35/00 (2006.01)
A61K 31/495 (2006.01)

(21) International Application Number:

PCT/US2022/049367

(22) International Filing Date:

09 November 2022 (09.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/277,976 10 November 2021 (10.11.2021) US

(71) Applicant: **CELGENE QUANTICEL RESEARCH, INC.** [US/US]; 9393 Town Centre Drive, Suite 110, San Diego, California 92121 (US).

(72) Inventors: **FILVAROFF, Ellen**; c/o CELGENE QUANTICEL RESEARCH, INC., 9393 Town Centre Drive, Suite 110, San Diego, California 92121 (US). **HANNA, Bishoy**; c/o CELGENE QUANTICEL RESEARCH, INC., 9393 Town Centre Drive, Suite 110, San Diego, California 92121 (US). **LAMBA, Manisha**; c/o CELGENE QUANTICEL RESEARCH, INC., 9393 Town Centre Drive, Suite 110,

San Diego, California 92121 (US). **ARONCHIK, Ida**; c/o CELGENE QUANTICEL RESEARCH, INC., 9393 Town Centre Drive, Suite 110, San Diego, California 92121 (US).

(74) Agent: **SIMKIN, Michele M.** et al.; FOLEY & LARDNER LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: BET INHIBITOR FOR TREATING GLIOBLASTOMA

(57) Abstract: The present application relates generally to methods for treating glioblastoma, or glioblastoma multiforme (GBM), with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, or the pharmaceutically acceptable salt thereof, which is a BET inhibitor.

FIG. 2



[Continued on next page]

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

22 June 2023 (22.06.2023)